All In Biotech

NDA 200677 · Recordati Rare

Signifor

Pasireotide Diaspartate · Subcutaneous · Somatostatin Analog

NovelOrphan

Last checked: Nov 19, 2026Latest source record: Jul 11, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Dec 14, 2012

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1

0 Phase 3, 0 recruiting

FAERS reports

1,194

962 serious, 108 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 17, 2026.

SIGNIFOR is a somatostatin analog indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative ( 1 ) 1.1 Cushing's Disease SIGNIFOR is indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.

Mechanism: SIGNIFOR is an injectable cyclohexapeptide somatostatin analogue. Pasireotide exerts its pharmacological activity via binding to somatostatin receptors (SSTRs). Five human somatostatin receptor subtypes are known: SSTR 1, 2, 3, 4, and 5. These receptor subtypes are expressed in different tissues under normal physiological conditions. Corticotroph tumor cells from Cushing's disease patients frequently over-express SSTR5 whereas the other receptor subtypes are often not expressed or are expressed at lower levels. Pasireotide binds and activates the SSTRs resulting in inhibition of ACTH...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 15, 2020 Supplement 6 · Efficacy LabelLetter
  • Dec 14, 2012 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelReviewLetter
3 products under this application
  • SIGNIFOR · PASIREOTIDE DIASPARTATE EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • SIGNIFOR · PASIREOTIDE DIASPARTATE EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • SIGNIFOR · PASIREOTIDE DIASPARTATE EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pasireotide Diaspartate" as an intervention, any sponsor and status, largest first.

All 1 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea163
  • hyperglycaemia144
  • diabetes mellitus136
  • fatigue125
  • drug ineffective122
  • blood glucose increased121
  • diarrhoea121
  • off label use114
  • headache88
  • vomiting83
  • dizziness74
  • hypoglycaemia62

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20121
201343
201494
2015120
2016116
2017106
201873
201986
2020116
202171
202286
202386
202467
202577
202651

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Signifor (Pasireotide Diaspartate)

2024 spending

$2.1M

Beneficiaries

19

107 claims

Per beneficiary

$110,547

$327.16 per unit

View as table
YearSpending
2020$0
2021$0
2022$789,420
2023$1,492,015
2024$2,100,391

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Recordati Rare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.